SCYX: SCYNEXIS Quarterly EPS earnings growth

Public company logo of SCYNEXIS (SCYX)

SCYNEXIS, Inc. (SCYX) has minimized internal costs and created a royalty lever by transitioning to the licensing of antifungal agents to third-party tech giants. The quarterly relative change in EPS captures this effect, with the parameter mark equal to 48.20. Management stability is ensured by the partnership with GSK and revenue transparency, while the company simultaneously expands its antifungal product portfolio for the hospital and pharmacy sectors.

SCYNEXIS Inc (SCYX) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/10/2026

Summary analytical data breakdowns for SCYNEXIS, Inc. (SCYX)

- share price and expert price forecast:
Stock Price scynexis.com|SCYX - Forecast Levels Chart
- market capitalization information:
Market Capitalization Scynexis|SCYX - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share SCYNEXIS|SCYX - Company Net Assets|Market Cap to Net Assets Ratio scynexis.com|SCYX - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital SCYNEXIS, Inc.|SCYX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity scynexis.com|SCYX - Company Cumulative Debt|Debt to Book Capitalization Ratio Scynexis|SCYX - Company Long-Term Indebtedness|Company Short-Term Debt SCYNEXIS|Quick Liquidity scynexis.com
- earnings and valuation multiples indicators:
SCYX - Net Financial Result|Projected Future Earnings SCYNEXIS, Inc.|SCYX - Price to Earnings Ratio|Projected Price to Earnings scynexis.com|SCYX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scynexis|SCYX - Operating profit before amortization|Net earnings per share (EPS TTM) SCYNEXIS|SCYX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months scynexis.com|SCYX - Earnings per share growth this year|Earnings growth forecast for next year SCYNEXIS, Inc.
Comprehensive company analysis:SCYNEXIS, Inc.
Flagship merchandise of scynexis.com

Quarterly EPS growth measures the rate of change in net income per share, allowing investors to assess capital generation efficiency over the short term. By analyzing quarterly EPS trends, one can compare market demand with actual returns, which for SCYNEXIS, Inc. (SCYX) depend directly on the stability of contract manufacturing for antifungal drugs and the continuity of their supply.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months MRNA (Moderna Inc)|PCVX (Vaxcyte Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tarsus Corp TARS|Quarterly EPS earnings growth CRMD|Year-over-year net earnings per share growth for the last 12 months serestherapeutics.com MCRB|Spero Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months ANTX (AN2 Therapeutics Inc)|PolyPid Limited - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months YS Biopharma Co., Ltd. LSB|iterumtx.com (ITRM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months BiomX (PHGE)|Year-over-year earnings per share growth for the last twelve months Soligenix Inc|Year-over-year earnings per share growth for the last 12 months SXTP (60 Degrees Pharma)|Year-over-year earnings per share growth for the last twelve months Oragenics, Inc. (OGEN)|Year-over-year net earnings per share change for the last twelve months OpGen Corporation